Patent Registration â€“ Protect your earth-moving ideas with PowerPatent software service for Online Patent Application
The Moderna Therapeutics, Inc. patent solves the following problem:
There are many problems by way of effecting protein expression. For example, introduced DNA becomes integrated into the host cell genomic DNA at certain frequencies, resulting in alteration and / or damage to the host cell genomic DNA. Another, heterologous deoxyribonucleic acid (DNA) was introduced into a cell can be inherited in daughter cells (whether or not the heterologous DNA integrated into the chromosome) or by children. Furthermore, assuming full delivery and no damage or integration into the host genome, there are many steps that must occur before the encoded proteins are made. Once inside the cell, the DNA must be transported into the nucleus, where it was written to RNA. The RNA was written out in the DNA must then enter the cytoplasm where it is translated into protein. Not just the multiple processing steps from the administered DNA to make proteins lag time before the generation of functional proteins, each step represents an opportunity for error and damage to the cell. Furthermore, it is known to be difficult to obtain DNA expression in cells as DNA often enters a cell, but not expressed or is expressed at reasonable rates or concentration. This can be a particular problem when DNA is introduced into primary cells or modified cell lines.
Our analysis of this patent is as follows:
Moderna Therapeutics, Inc.’s patent US 9221891 B2 deals with In vivo production of proteins.
The invention relates to compositions and methods for the preparation, performance and use of therapeutic polynucleotides, first transcripts and mmRNA molecules.
The revolutionary PowerPatent provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.